Regeneron Pharmaceuticals Profile

329.04
USD 2.93  0.88%
78%
40%

Exercise or conversion by Roberts William of 10000 shares of Regeneron Pharmaceuticals subject to Rule 16b-3

Regeneron Pharmaceuticals insider trading alert for exercise of non-qualified stock option (right to buy) by Roberts William, VP Regul Devel Med Safety, on June 23, 2018. This event was filed by Regeneron Pharmaceuticals with SEC on 2011-01-11. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Regeneron Pharmaceuticals Summary

Regeneron Pharmaceuticals (REGN) is traded on NASDAQ in USA. It is located in NEW YORK, U.S.A and employs 6,401 people. Regeneron Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Large-Cap' category with current market capitalization of 35.77 B. Regeneron Pharmaceuticals conducts business under Healthcare sector and is part of Biotechnology industry. This company has 105.84 M outstanding shares of which 2.62 M shares are at this time shorted by private and institutional investors with about 2.65 trading days to cover. REGENERON PHARMAC currently holds about 1.62 B in cash with 1.08 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 15.1.
Check Regeneron Pharmaceuticals Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Odds Below 329.04HorizonTargetOdds Above 329.04
92.98%30 days 329.04 6.91%
Based on normal probability distribution, the odds of Regeneron Pharmaceuticals to move above current price in 30 days from now is about 6.91% (This Regeneron Pharmaceuticals probability density function shows the probability of Regeneron Pharmaceuticals Stock to fall within a particular range of prices over 30 days) .

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Blackrock IncCommon Shares6 M2.1 B
Vanguard Group IncCommon Shares5.6 M1.9 B
View Regeneron Pharmaceuticals Diagnostics

Selected Regeneron Pharmaceuticals Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Regeneron Pharmaceuticals Against Markets

Current Ratings

Regeneron Pharmaceuticals 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
26 
Chance of
Financial Distress (0 to 100%)
1 
Equity ratings for Regeneron Pharmaceuticals are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in USA and traded on NASDAQ. It employs 6401 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameRegeneron Pharmaceuticals
President CEO, DirectorLeonard SchleiferView All
Thematic Classifications
Active Investing Ideas
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Specialization
Healthcare, Pharmaceuticals And Biosciences
InstrumentUSA Stock View All
RegionNorth America
LocationNEW YORK, U.S.A
Business Address777 Old Saw Mill River Road
Foreign Associates
ExchangeNASDAQ
CIK Number00872589.0
ISINUS75886F1075
CUSIP75886F107
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.regeneron.com
Contact Number914 847 7000
CurrencyUSD - US Dollar

Recommendations

Regeneron Pharmaceuticals Analyst Recommendations
Target PriceAdvice# of Analysts
428.29Hold14Odds
Regeneron Pharmaceuticals current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Regeneron Pharmaceuticals Analyst Advice  

Earnings

Regeneron Pharmaceuticals Earnings Estimates
EPSEstimate Date
Quarterly Estimate2.5May 4, 2017
Regeneron Pharmaceuticals normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  

Directors

Regeneron Pharmaceuticals Corporate Directors
Charles Baker Independent Director
Joseph Goldstein Independent Director, Ph.D
Anthony Coles Independent Director
Additionally take a look at Your Equity Center. Please also try Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.